Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.66 -0.02 (-1.19%)
At close: Oct 21, 2026 · 4:00 PM EDT

Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021)

Updated

Transcode Therapeutics (RNAZ) reported Convertible Debt of $2.13 million for Q2 2021.

Analysis

Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021) Analysis & Trends

At the end of FY2020, Transcode Therapeutics posted Convertible Debt of $2.09 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Transcode Therapeutics 1.63 Mn -40.26 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 2.13 Mn
Dec 31, 2020 2.09 Mn
API Access

Transcode Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=RNAZ&period=max&api_key=YOUR_API_KEY